Albireo is a biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.
We value diversity and strive to create an inviting and inclusive environment. We seek to inspire trust and respect by taking responsibility for our actions, maintaining high ethical standards and encouraging honest and straightforward communication.
We work with urgency as part of our commitment to patients. We must have courage to make tough decisions for the benefit of the patient and passion to drive outcomes that reduce burden on families.
Our focus is on the highest value and impactful work first. We believe in fit for purpose - keep it simple and learn from our mistakes. Encourage healthy dialogue to drive towards high-quality solutions and innovations.
We believe that people and relationships ultimately determine success. We are focused on creating a thriving, inclusive and collaborative community. We encourage healthy dialog to drive towards high-quality solutions. We are trusted and empowered to manage their health, family and workload.